SCHEMBL5145235

SCHEMBL5145235

O=C1NC(=S)NC(=O)C1=Cc1ccc(-c2ccc(C(=O)O)c(Cl)c2)o1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.78
AURKB Q96GD4 1/20 0.78
SIRT2 Q8IXJ6 4/20 0.75
BRAF P15056 5/20 0.66
KDM4E B2RXH2 4/20 0.64
KMT2A Q03164 4/20 0.64
TDP1 Q9NUW8 4/20 0.64
MAPT P10636 3/20 0.64
ALDH1A1 P00352 3/20 0.64
POLB P06746 3/20 0.64
PKM P14618 2/20 0.64
CTDSP1 Q9GZU7 2/20 0.64
MEN1 O00255 2/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
KEAP1 Q14145 2/20 0.63
NFE2L2 Q16236 2/20 0.63
GSK3A P49840 3/20 0.60
GSK3B P49841 3/20 0.60
APEX1 P27695 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5147286 0.90 GSK3A (0.76) AURKAAURKBSIRT2BRAFKDM4E
SCHEMBL5147289 0.90 GSK3A (0.76) AURKAAURKBSIRT2BRAFKDM4E
SCHEMBL1435462 0.88 AURKA (1.00) AURKAAURKBSIRT2BRAFKDM4E
SCHEMBL5994115 0.86 SIRT2 (1.00) AURKAAURKBSIRT2BRAFKMT2A
SCHEMBL13587001 0.83 SIRT2 (0.80) AURKAAURKBSIRT2BRAFKDM4E
SCHEMBL1064843 0.83 GSK3A (0.81) AURKAAURKBSIRT2BRAFKMT2A
SCHEMBL1067629 0.82 BRAF (0.85) AURKAAURKBBRAFKDM4EKMT2A
SCHEMBL1067626 0.82 BRAF (0.85) AURKAAURKBBRAFKDM4EKMT2A
SCHEMBL5164488 0.82 KMT2A (0.71) AURKAAURKBSIRT2KDM4EKMT2A
SCHEMBL5145124 0.81 GSK3A (0.76) AURKAAURKBSIRT2KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 AURKA 4704/4885AURKB 3812/4885SIRT2 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.